<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00575354</url>
  </required_header>
  <id_info>
    <org_study_id>NMU-2579-6FW</org_study_id>
    <secondary_id>#NMU072036</secondary_id>
    <nct_id>NCT00575354</nct_id>
  </id_info>
  <brief_title>Comparison of Sevoflurane and Isoflurane Anesthesia for Benign Breast Tumor Excision</brief_title>
  <acronym>CSIABTEC</acronym>
  <official_title>Anesthesia With Sevoflurane and Isoflurane for Excision Surgeries in Benign Breast Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Generally, benign breast tumors are excised under the local anesthesia. But such action was
      so invasive that every patient would experience the physiological and psychological stimuli
      unavoidably. Sevoflurane was advised as a better inhalational anesthesic for its &quot;easy
      come,easy go&quot; property during short-lasting operations than isoflurane. We purposed that
      sevoflurane would be a superior anesthesic for benign breast tumor excision than isoflurane
      with relative less alteration in hemodynamics, less postoperative side effects and
      easily-control the depth of anesthesia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time of induction, maintenance and resuscitation</measure>
    <time_frame>0h to the end of the operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraoperative hemodynamics; Postoperative side effects;</measure>
    <time_frame>0h to 24h after the end of the operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sevoflurane: induction 3-6%, maintenance 2-3%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isoflurane: induction 3-6%, maintenance 2-3%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>3-6% sevoflurane inhaled for anesthesia induction, and 2-3% sevoflurane was used to maintain the anesthesia till the end of the operation.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Sevofrane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoflurane</intervention_name>
    <description>3-6% isoflurane inhaled for anesthesia induction, and 2-3% isoflurane was used to maintain the anesthesia till the end of the operation.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chinese

          -  Diagnosed benign breast tumor patients

          -  18-64 yrs

        Exclusion Criteria:

          -  Allergic to any interventional drugs

          -  Organic dysfunction

          -  Long-lasting PACU staying
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>XiaoFeng Shen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nanjing Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nanjing Maternal and Child Care Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2007</study_first_submitted>
  <study_first_submitted_qc>December 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2007</study_first_posted>
  <last_update_submitted>April 18, 2008</last_update_submitted>
  <last_update_submitted_qc>April 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2008</last_update_posted>
  <responsible_party>
    <name_title>XiaoFeng Shen</name_title>
    <organization>Nanjing Medical University</organization>
  </responsible_party>
  <keyword>Sevoflurane</keyword>
  <keyword>Isoflurane</keyword>
  <keyword>Breast tumor</keyword>
  <keyword>Anesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Isoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

